<?xml version='1.0' encoding='utf-8'?>
<document id="31793171"><sentence text="Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability."><entity charOffset="97-109" id="DDI-PubMed.31793171.s1.e0" text="Rosuvastatin" /></sentence><sentence text="AZD5718 is a first-in-class small-molecule anti-inflammatory drug with the potential to reduce the residual risk of cardiovascular events after myocardial infarction in patients receiving lipid-lowering statin therapy" /><sentence text=" Leukotrienes are potent proinflammatory and vasoactive mediators synthesized in leukocytes via 5-lipoxygenase and 5-lipoxygenase-activating protein (FLAP)"><entity charOffset="1-13" id="DDI-PubMed.31793171.s3.e0" text="Leukotrienes" /></sentence><sentence text=" AZD5718 is a FLAP inhibitor that dose-dependently reduced leukotriene biosynthesis in a first-in-human study"><entity charOffset="59-70" id="DDI-PubMed.31793171.s4.e0" text="leukotriene" /></sentence><sentence text=" We enrolled 12 healthy men in a randomized, open-label, crossover, single-dose phase 1 pharmacokinetic study of AZD5718 to investigate a potential drug-drug interaction with rosuvastatin, and the effects of formulation and food intake (ClinicalTrials"><entity charOffset="175-187" id="DDI-PubMed.31793171.s5.e0" text="rosuvastatin" /></sentence><sentence text="gov identifier: NCT02963116)"><entity charOffset="16-27" id="DDI-PubMed.31793171.s6.e0" text="NCT02963116" /></sentence><sentence text=" Rosuvastatin (10 mg) were absorbed more rapidly when coadministered with AZD5718 (200 mg), probably owing to weak inhibition of hepatic statin uptake, but relative bioavailability was unaffected (geometric least-squares mean ratio [GMR], 100%; 90% confidence interval [CI], 86%-116%)"><entity charOffset="1-13" id="DDI-PubMed.31793171.s7.e0" text="Rosuvastatin" /></sentence><sentence text=" AZD5718 pharmacokinetics were unaffected by coadministration of rosuvastatin"><entity charOffset="65-77" id="DDI-PubMed.31793171.s8.e0" text="rosuvastatin" /></sentence><sentence text=" AZD5718 (200 mg) was absorbed less rapidly when formulated as tablets than oral suspension, with reduced relative bioavailability (GMR, 72%; 90%CI, 64%-80%)" /><sentence text=" AZD5718 absorption was slower when 200-mg tablets were taken after a high-fat breakfast than after fasting, but relative bioavailability was unaffected (GMR, 96%; 90%CI, 87%-106%)" /><sentence text=" In post hoc pharmacodynamic simulations, plasma leukotriene B4 levels were inhibited by &gt;90% throughout the day following once-daily AZD5718, regardless of formulation or administration with food" /><sentence text=" AZD5718 was well tolerated, with no severe or serious adverse events" /><sentence text=" These data supported the design of a phase 2a efficacy study of AZD5718 in patients with coronary artery disease" /><sentence text="" /></document>